Growth Metrics

Quest Diagnostics (DGX) Cash & Current Investments (2016 - 2026)

Quest Diagnostics has reported Cash & Current Investments over the past 18 years, most recently at $393.0 million for Q1 2026.

  • Quarterly results put Cash & Current Investments at $393.0 million for Q1 2026, up 109.04% from a year ago — trailing twelve months through Mar 2026 was $393.0 million (up 109.04% YoY), and the annual figure for FY2025 was $420.0 million, down 23.5%.
  • Cash & Current Investments reached $393.0 million in Q1 2026 per DGX's latest filing, down from $420.0 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $790.0 million in Q2 2022 and bottomed at $126.0 million in Q2 2023.
  • Median Cash & Current Investments over the past 5 years was $420.0 million (2025), compared with a mean of $438.6 million.
  • The largest annual shift saw Cash & Current Investments tumbled 84.05% in 2023 before it skyrocketed 434.27% in 2024.
  • Over 5 years, Cash & Current Investments stood at $315.0 million in 2022, then skyrocketed by 117.78% to $686.0 million in 2023, then decreased by 19.97% to $549.0 million in 2024, then dropped by 23.5% to $420.0 million in 2025, then fell by 6.43% to $393.0 million in 2026.
  • Business Quant data shows Cash & Current Investments for DGX at $393.0 million in Q1 2026, $420.0 million in Q4 2025, and $432.0 million in Q3 2025.